Sign In
Buy FUSN
$13.26
+0 (+0%)
At Close: Sep 04, 2020
Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
07:45am, Wednesday, 07'th Feb 2024
HAMILTON, ON and BOSTON , Feb. 7, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as preci
Wall Street Analysts Believe Fusion Pharmaceuticals Inc. (FUSN) Could Rally 35.09%: Here's is How to Trade
10:55am, Thursday, 25'th Jan 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Fusion Pharmaceuticals Inc. (FUSN). While the effectiveness of this highly sought-after metric is ques
What Makes Fusion Pharmaceuticals Inc. (FUSN) a New Strong Buy Stock
01:01pm, Wednesday, 17'th Jan 2024
Fusion Pharmaceuticals Inc. (FUSN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near
Finding the Best Cheap Stocks Under $10 to Buy in 2024
04:33pm, Tuesday, 16'th Jan 2024
Let's take a look at the screen and a few of the over 50 highly-ranked cheap stocks to consider buying in January.
What Makes Fusion Pharmaceuticals Inc. (FUSN) a Strong Momentum Stock: Buy Now?
01:33pm, Tuesday, 16'th Jan 2024
Does Fusion Pharmaceuticals Inc. (FUSN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is it a Good Idea to Buy Fusion Pharmaceuticals (FUSN) Stock Now?
09:47am, Tuesday, 16'th Jan 2024
Here, we discuss some reasons why investing in Fusion Pharmaceuticals (FUSN) stock now may turn out to be a prudent move.
How Fusion Pharmaceuticals (FUSN) Stock Stands Out in a Strong Industry
09:46am, Wednesday, 10'th Jan 2024
Fusion Pharmaceuticals (FUSN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Does Fusion Pharmaceuticals Inc. (FUSN) Have the Potential to Rally 47.76% as Wall Street Analysts Expect?
07:33pm, Tuesday, 09'th Jan 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 47.8% in Fusion Pharmaceuticals Inc. (FUSN). While the effectiveness of this highly sought-after metric is ques
Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday
02:17pm, Thursday, 28'th Dec 2023
Fusion Pharmaceuticals (FUSN) surges to a new record level 52-week high after analysts at Raymond James upgraded its rating following the buyout announcements for two comparable companies.
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
07:50am, Wednesday, 27'th Dec 2023
Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceutic
4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow
09:46am, Wednesday, 20'th Dec 2023
Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.
Here's Why Fusion Pharmaceuticals Inc. (FUSN) is a Great Momentum Stock to Buy
01:32pm, Friday, 08'th Dec 2023
Does Fusion Pharmaceuticals Inc. (FUSN) have what it takes to be a top stock pick for momentum investors? Let's find out.
How Much Upside is Left in Fusion Pharmaceuticals Inc. (FUSN)? Wall Street Analysts Think 162%
11:17am, Monday, 27'th Nov 2023
The mean of analysts' price targets for Fusion Pharmaceuticals Inc. (FUSN) points to a 162% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agree
10 ‘better values' in the stock market, selected for the next two years
12:49pm, Thursday, 16'th Nov 2023
Since market valuations are always changing, along with outlooks for corporate revenue and earnings, any list of favored stocks is only a snapshot. Repeating the same analysis in the near term might l
Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Tops Revenue Estimates
09:46am, Tuesday, 07'th Nov 2023
Fusion Pharmaceuticals Inc. (FUSN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.55 per share a year ago.
